

December 9, 2019

Press Release (Translation)

Nobelpharma Co., Ltd.

Launching Sales of Retympa® 250 µg Set for Otology
a Treatment for Tympanic Membrane Perforation

Nobelpharma Co., Ltd. (Head Office: Tokyo, President: Jin Shiomura) is announcing that the Company has launched sales of Retympa® 250µg Set for Otology ("Retympa®") on December 9, 2019, with tympanic membrane perforation as its indication.

Retympa® consists of a freeze-dried product containing trafermin (genetic recombination) as an active ingredient and accompanying solution and gelatin sponge for tympanic membrane.

In the tympanic membrane closure treatment using Retympa®, gelatin sponge for tympanic membrane infiltrated with trafermin (genetic recombination) is placed in the tympanic membrane perforation. Then, in order to prevent drying and infection, the surface of the gelatin sponge is glued and closed with tissue adhesive, thereby maintaining the tympanic membrane's regenerative environment conducive to closing the tympanic membrane. As it does not require an autograft, the treatment is minimally invasive, and it can also be done at an outpatient site owing to the simple procedure.

There are no countries or regions outside Japan for which Retympa® has been approved for the indication of tympanic membrane perforation.

We will continue to contribute to society by providing pharmaceuticals and medical devices for unmet needs.

【Contact for more information】

Nobelpharma Co., Ltd.

Kozo Hayase

Executive Officer, Head of Administrative Affairs & Corporate Planning

Tel: 03-6670-3800

About Nobelpharma

Nobelpharma has contributed to the provision of necessary treatments for neglected diseases through research and development of pharmaceuticals and medical devices since 2003. Aiming to develop products that respond to unmet needs, we prioritize the development of pharmaceuticals and medical devices strongly desired by patient groups and medical associations. Currently, we have obtained approval to manufacture and sell 16 products, mainly for unmet needs, and 10 products are designated as orphan drugs and 2 products are designated Sakigake.